Analyst Price Targets — ABBV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 8:32 pm | — | Canaccord Genuity | $262.00 | $203.71 | TheFly | AbbVie initiated with a Buy at Canaccord |
| April 10, 2026 10:55 am | Vamil Divan | Guggenheim | $249.00 | $210.15 | TheFly | AbbVie price target raised to $249 from $242 at Guggenheim |
| April 8, 2026 11:33 am | — | Cantor Fitzgerald | $240.00 | $211.59 | TheFly | AbbVie price target lowered to $240 from $250 at Cantor Fitzgerald |
| February 24, 2026 9:07 pm | Trung Huynh | RBC Capital | $260.00 | $228.44 | StreetInsider | RBC Capital Starts Abbvie (ABBV) at Outperform |
| February 19, 2026 9:17 pm | — | Barclays | $275.00 | $224.35 | TheFly | AbbVie initiated with an Overweight at Barclays |
| February 18, 2026 11:41 am | — | Piper Sandler | $299.00 | $232.86 | TheFly | AbbVie price target raised to $299 from $289 at Piper Sandler |
| February 5, 2026 12:24 pm | — | UBS | $230.00 | $217.42 | TheFly | AbbVie price target lowered to $230 from $240 at UBS |
| February 4, 2026 7:35 pm | Gavin Clark-Gartner | Evercore ISI | $228.00 | $217.02 | TheFly | AbbVie price target lowered to $228 from $232 at Evercore ISI |
| January 28, 2026 11:57 am | Asad Haider | Goldman Sachs | $223.00 | $219.77 | StreetInsider | Goldman Sachs Reiterates Neutral Rating on Abbvie (ABBV) Ahead of Earnings |
| January 20, 2026 9:29 am | — | Berenberg Bank | $275.00 | $214.35 | TheFly | AbbVie price target raised to $275 from $270 at Berenberg |
Latest News for ABBV
Alley Investment Management Company LLC trimmed its position in shares of AbbVie Inc. (NYSE: ABBV) by 5.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 112,247 shares of the company's stock after selling 6,845 shares during the quarter. AbbVie accounts for 3.0%
AbbVie (ABBV) closed at $203.71 in the latest trading session, marking a -2.24% move from the prior day.
AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors.
ABBV's oncology unit faces declining Imbruvica sales and pricing pressure, likely dragging Q1 revenues despite growth from newer cancer therapies.
Microsoft, AbbVie and BHP anchor today???s top analyst reports, highlighting AI growth, drug pipeline strength and rising commodity output shaping outlooks.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.